Security key
Y1R80M106
CytoMed Therapeutics Ltd - Ordinary Shares, no par value per share (GDTC)
CUSIP: Y1R80M106
Q3 2026 13F Holders as of 30 Sep 2026
- Security type / class
- Equity / Ordinary Shares, no par value per share
- Total 13F shares
- 26,965
- Total 13F value
- $24,447
- Share change
- +19,933
- SEC-reported price per share
- $0.91
- Number of holders
- 1
- Value change
- +$17,204
- Number of buys
- 1
- Number of sells
- 1
- Shares outstanding
- 11,934,325
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2026
Institutions
1
Top holders
1
GDTC full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q2 2026
CytoMed Therapeutics Ltd SEC filings
CytoMed Therapeutics Ltd company facts
Broader feeds
Reporting periods
Holder history for CUSIP Y1R80M106
Recent filing periods:
Ownership snapshot
Top reported holders of GDTC - CytoMed Therapeutics Ltd - Ordinary Shares, no par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
28 Consultants Ltd
Disclosed value leader
Choo Chee Kong
Comparable rows
1/13
Latest evidence
14 Jul 2026
13D/G
3/4/5
13F
Lead comparable stake: 7.6%
12 rows are not safely comparable across share classes.
13D/G row: 28 Consultants Ltd
Showing 1-6 of 13 holder rows.
Quick read
28 Consultants Ltd leads the comparable SEC ownership view at 7.6%.
1 of 13 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens 28 Consultants Ltd's linked filing trail.
Comparable ownership
Top 1
28 Consultants Ltd
7.6%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 13 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| 28 Consultants Ltd |
13D/G
|
7.6%
Reported 13D/G
· 17 Feb 2025
|
$2,095,145
880,313 shares
|
$0 | 17 Feb 2025 |
| Choo Chee Kong |
3/4/5
Director, 10%+ Owner
|
—
mixed-class rows
|
$3,078,742
3,310,261 shares
mixed-class rows
|
+$428,778 | 14 Jul 2026 |
| Glorious Finance Ltd |
3/4/5
10%+ Owner
|
—
denominator unverified
|
—
4,653,604 shares
|
— | 31 Mar 2023 |
| Shu Wang |
3/4/5
10%+ Owner
|
—
denominator unverified
|
—
883,858 shares
|
— | 31 Mar 2023 |
| Yoong Ying Tan |
3/4/5
Chief Corporate Officer
|
—
denominator unverified
|
$24,234
25,781 shares
|
— | 18 Mar 2026 |
| Yvonne Goh |
3/4/5
Chief Financial Officer
|
—
denominator unverified
|
$24,234
25,781 shares
|
— | 18 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
26,965
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2026 vs Q2 2026 Across Filers
Q2 2026 holders
3
Q3 2026 holders
1
Holder diff
-2
| Investor | Q2 2026 Shares | Q3 2026 Shares | Share Diff | Share Chg % | Q2 2026 value | Q3 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend